Found 162 articles for: "infliximab"
Nail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience
August 2022 | Volume 21 | Issue 8 | Editorials | 914 | Copyright © August 2022
The aim of this retrospective study of patients affected by plaque psoriasis who underwent tildrakizumab therapy was to describe and compare the response of the nail psoriasis and the plaque psoriasis...
Read MoreAn Up-to-Date Approach to the Management of Dissecting Cellulitis
July 2022 | Volume 21 | Issue 7 | Features | 800 | Copyright © July 2022
Dissecting cellulitis of the scalp (DCS) also known as perifolliculitis capitis abscedens et suffodiens (PCAS) is a chronic, relapsing, inflammatory dermatosis consisting of edematous sterile pustules...
Read MoreSubgroup Analyses by European Country-Specific Reimbursement Requirements Confirm Efficacy for Ixekizumab in Psoriasis
June 2022 | Volume 21 | Issue 6 | Original Article | 659 | Copyright © June 2022
Background: Biologic drugs are generally recommended for treating moderate-to-severe psoriasis. While eligibility criteria are primarily defined by clinical treatment guidelines, acce...
Read MoreProbiotics Supplementation Improves Quality of Life, Clinical Symptoms, and Inflammatory Status in Patients With Psoriasis
June 2022 | Volume 21 | Issue 6 | Original Article | 637 | Copyright © June 2022
Background: Studies have proposed a link between psoriasis and imbalanced gut microbiome. Therefore, the modulation of the gut microbiota with probiotics may improve clinical outcomes...
Read MoreFuture Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline
May 2022 | Volume 21 | Issue 5 | Original Article | 496 | Copyright © May 2022
Over the last decade, major advances in antifungal drug development have occurred. Novel drugs in the pipeline include ME1111, MAT2203, rezafungin, ibrexafungerp, olorofim, fosmanogepix, MGCD290, VT-1...
Read MoreLong-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study
April 2022 | Volume 21 | Issue 4 | Original Article | 399 | Copyright © April 2022
Background: There is a paucity of long-term real-world evidence comparing the effectiveness of ixekizumab (IXE) and adalimumab (ADA). We compared real-world treatment patterns of IXE-...
Read MoreBotulinum Toxin in Hidradenitis Suppurativa: A Systematic Review
April 2022 | Volume 21 | Issue 4 | Original Article | 408 | Copyright © April 2022
Background: Hidradenitis suppurativa disproportionately affects women, minorities, and skin of color. Botulinum toxin is a potential therapy; however, literature regarding its utility...
Read MoreLong-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics
April 2022 | Volume 21 | Issue 4 | Original Article | 364 | Copyright © April 2022
Background: Despite the emergence of multiple biologic drug options for psoriasis, unmet treatment needs remain. Biologic therapies can vary in their effectiveness and adverse events,...
Read MoreRefractory Dissecting Cellulitis of the Scalp Treated With Risankizumab
March 2022 | Volume 21 | Issue 3 | Case Reports | 313 | Copyright © March 2022
Perifolliculitis capitis abscedens et suffodiens or dissecting cellulitis (DC) is a rare and chronic disease with a predilection for the occipital, vertex, and parietal scalp. DC is characterized by m...
Read MoreUstekinumab in the Management of Hidradenitis Suppurativa: A Retrospective Study
March 2022 | Volume 21 | Issue 3 | Editorials | 319 | Copyright © March 2022
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by the formation of recurrent abscesses in apocrine-bearing areas. In advanced stages, chronic inflammation leads to...
Read MoreTreatment of Nail Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 146 | Copyright © February 2022
Nail psoriasis has a considerable negative impact on the quality of life by limiting the patient’s household chores, professional activities and social interactions. Treatment for nail psoriasis...
Read MoreBiological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis
October 2021 | Volume 20 | Issue 10 | Original Article | 1063 | Copyright © October 2021
While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We re...
Read MoreReview of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis
August 2021 | Volume 20 | Issue 8 | Original Article | 837 | Copyright © August 2021
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA)...
Read MoreHospitalization in Patients with Psoriasis: Impact of Biological Therapies on Temporal Evolution
February 2021 | Volume 20 | Issue 2 | Original Article | 208 | Copyright © February 2021
Background: Psoriasis is an immunomediated disease mostly controlled at the outpatient level, although there is a low percentage of patients that require systemic drugs or even hospit...
Read MoreSuccessful Treatment of Periorificial Dermatitis With Novel Narrow Spectrum Sarecycline
January 2021 | Volume 20 | Issue 1 | Case Reports | 98 | Copyright © January 2021
Broad spectrum tetracyclines are a well-known, widely used, and often successful treatment for use in inflammatory skin pathologies such as acne and rosacea. However, the steady rise of antibiotic res...
Read MoreUveitis for Dermatologists: A Review
December 2020 | Volume 19 | Issue 12 | Original Article | 1192 | Copyright © December 2020
Certain dermatologic conditions and drugs used for their treatment are associated with uveitis, a vision-threatening group of inflammatory eye diseases. Dermatologists may therefore be the first healt...
Read MoreTherapies for Psoriasis: Clinical and Economic Comparisons
November 2020 | Volume 19 | Issue 11 | Original Article | 1101 | Copyright © November 2020
Background: Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new devel- opment in the field. With the recent availability of a ...
Read MoreNail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis
August 2020 | Volume 19 | Issue 8 | Original Article | 741 | Copyright © August 2020
Background: Presence of nail psoriasis in patients with plaque psoriasis may be an indicator of greater disease severity. Previously, patients with nail psoriasis have had delayed ski...
Read MoreOral Metformin for Treating Dermatological Diseases: A Systematic Review
August 2020 | Volume 19 | Issue 8 | Original Article | 713 | Copyright © August 2020
Introduction:Metformin is an antihyperglycemic medication most commonly used to treat Type II Diabetes Mellitus with promising off-label application for the treatment of hidradenit...
Read MoreSafety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies Errata
June 2020 | Volume 19 | Issue 6 | Editorials | 573 | Copyright © June 2020
Erratum for article "Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies." Retriev...
Read More